Alligator Bioscience
Alligator Bioscience AB is a Swedish clinical-stage biotechnology company developing tumor-directed antibody immunotherapies for cancer treatment. The company utilizes its proprietary FIND and RUBY technology platforms to engineer bispecific and mono-specific antibodies that stimulate immune responses selectively within the tumor microenvironment. Main revenue drivers currently comprise research partnership licensing fees, development milestone payments, and capital markets financing. Alligator Bioscience targets clinical oncology research networks, biopharmaceutical collaboration partners, and cancer patients across Western Europe and North America. The company holds a specialized niche position in Swedish immuno-oncology research and bispecific antibody engineering. Headquartered in Lund, Sweden, Alligator Bioscience AB is listed on Nasdaq Stockholm.
2 of the funds FundTelligence covers report a position in Alligator Bioscience.
- Legal name
- Alligator Bioscience AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 2
Funds holding Alligator Bioscience
- Storebrand Sverige Småbolag Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)